MK-677 as a GH alternative: what the evidence actually says

What did @averyfisk_ actually say?

The creator laid out a week-by-week timeline for IGF-1 LR3, a synthetic analog of insulin-like growth factor 1. They claim pumps improve in weeks one to two, recovery gets "seriously" better by weeks three to six, lean muscle and connective tissue gains show up at two to three months, and hyperplasia, meaning new muscle cell creation, kicks in at months three to six. They pitched it as a viable alternative to growth hormone for people "not ready for that next step."

They also recommended 50 to 100 micrograms daily, dosed pre-workout into the muscle being trained, and described it as something you can add to an existing cycle. That dosing guidance is worth flagging immediately: this is an unregulated research compound with no approved human dose, and presenting specific microgram numbers as casual advice skips over real safety considerations.

Does the science back this up?

Partially, but the evidence base is far thinner than the confident timeline suggests. Most of what we actually know about IGF-1 LR3 comes from animal studies and in vitro research, not controlled human trials. The hyperplasia claim in particular is almost entirely extrapolated from rodent and cell culture data.

IGF-1 itself is well-studied. It does play a documented role in muscle protein synthesis, satellite cell activation, and connective tissue repair. Adams and McCue (1998, American Journal of Physiology) showed IGF-1 isoforms stimulate muscle hypertrophy and satellite cell proliferation in animal models. The LR3 modification extends the half-life of IGF-1 by reducing binding protein affinity, which is the pharmacological rationale for the compound. That part is legitimate science. But the creator's week-by-week human timeline reads like anecdotal bro-science dressed up as a protocol. No published human study has validated a "weeks one to two, expect pumps" progression for this specific analog at these doses.

What did they get wrong (or right)?

Credit where it is due: the creator is correct that IGF-1 LR3 has a longer active window than native IGF-1 due to reduced binding protein affinity, and that connective tissue remodeling is a legitimate downstream effect of IGF-1 signaling. The general point that anabolic gains take weeks to manifest is also physiologically sound.

Where things go sideways is the hyperplasia claim. The creator says "there's no other peptide that actually does this," positioning muscle cell hyperplasia as a confirmed, unique selling point. Human skeletal muscle hyperplasia is genuinely contested in the literature. Most exercise scientists accept hypertrophy, enlargement of existing fibers, as the primary mechanism of muscle growth in humans. True hyperplasia, net new fiber creation, has limited and inconsistent human evidence. Bamman et al. (2004, Journal of Applied Physiology) found some evidence of satellite cell-driven fiber splitting under extreme training loads, but it is nowhere near the settled science the creator implies. Presenting hyperplasia as a guaranteed month-three outcome is misleading.

The "GH alternative" framing is also a stretch. Growth hormone and IGF-1 LR3 have overlapping but distinct mechanisms. Calling one an alternative to the other oversimplifies a complex endocrine relationship.

What should you actually know?

IGF-1 LR3 is not approved by the FDA for human use. It is classified as a research compound, which means manufacturing quality, purity, and dosing consistency are not standardized. That is not a small caveat. Studies on contamination and mislabeling of research peptides are a legitimate concern, and injecting an unverified compound carries infection and systemic risks that no TikTok timeline can account for.

Beyond regulatory status, there are real safety signals. IGF-1 dysregulation is associated with increased cancer cell proliferation risk in some research contexts. Sandhu et al. (2002, Journal of the National Cancer Institute) found elevated circulating IGF-1 correlated with increased colorectal cancer risk in a large prospective cohort. That does not mean IGF-1 LR3 causes cancer, but it does mean the "it's just like a peptide, it's safe" framing deserves more scrutiny than this video gives it. Hypoglycemia is also a documented acute risk with IGF-1 analogs due to insulin-like activity. Anyone considering peptide therapy should be doing so under clinical supervision with bloodwork, not based on a TikTok dosing protocol.

Bottom line: should you trust this timeline?

The broad strokes of IGF-1 biology are not invented. But a confident week-by-week timeline presented as if it comes from clinical data is not honest about what the evidence actually shows. The hyperplasia claim is the biggest red flag here. It is not a confirmed human outcome at these doses or timescales, and framing it as a unique, guaranteed effect of this compound is misleading. If you are exploring peptide therapy for recovery or body composition, a conversation with a licensed provider who can review your labs and health history is the appropriate starting point.